Safety and Efficacy of Romiplostim in Treatment of Chronic ITP in Children

Safety and Efficacy of Romiplostim in Treatment of Chronic ITP in Children

The aim is to evaluate safety and efficacy of Romiplostim in the treatment of chronic ITP in children

Inclusion Criteria:

• Patients aged between 1 and 18 years
• Diagnosis of chronic ITP
• Refractory to or intolerant of first-line therapies (e.g.corticosteroids , intravenous immunoglobulin [ IVIG ] , and oral eltrombopag )
• Platelet count<30,000/µL, or evidence of bleeding or risk of bleeding with platelet count<50,000/µL.
• Written informed consent (or parental/guardian consent for minors)

Exclusion Criteria:

• Evidence of secondary thrombocytopenia (e.g., HIV, HCV, systemic lupus erythematosus)
• congenital thrombocytopenia
• Age < 1year or more than 18 years
• Aplastic anemia
• Known hypersensitivity to romiplostim or any of its components